研究者詳細 - 佐治　重衡

論文 - 佐治　重衡

分割表示193 件中 1 - 20 件目／全件表示 >>

Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy.

Ito M, Amari M, Sato A, Hikichi M, Tsurumi N, Otofuji H, Saji S.

Breast Cancer Res Treat. 209 ( 3 ) 503 - 512 2025年2月

Merging of the Fukushima Health Management Survey With the National and Local Cancer Registry to Refine the Detection of Thyroid Cancer Cases After the 2011 Fukushima Daiichi Nuclear Power Plant Accident

Kimura-Tsuchiya R, Nagao M, Saji S, Hayashi F, Ohira T, Shimura H, Furuya F, Suzuki S, Suzuki S, Ishikawa T, Yokoya S, Ohto H, Yasumura S.

Cancer Med 14 ( 3 ) e70610 2025年2月

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.

Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B; TROPION-Breast01 Investigators.

J Clin Oncol. 43 ( 3 ) 285 - 296 2025年1月

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.

Yamashita T, Saji S, Takano T, Naito Y, Tsuneizumi M, Yoshimura A, Takahashi M, Tsurutani J, Iwatani T, Kitada M, Tada H, Mori N, Higuchi T, Iwasa T, Araki K, Koizumi K, Hasegawa H, Uchida Y, Morita S, Masuda N.

J Clin Oncol. JCO2401888 2025年1月

Effect of Combined Exercise and Nutrition Interventions During Inpatient Chemotherapy in Acute Leukemia and Malignant Lymphoma Patients: A Randomized Controlled Trial.

Kasahara R, Morishita S, Fujita T, Jinbo R, Kubota J, Takano A, Takahashi S, Kisara S, Jinbo K, Yamamoto Y, Kakuta M, Kai T, Shiga Y, Kimura H, Furukawa M, Saji S

Nutrition and cancer 77 ( 1 ) 115 - 123 2025年

Development of cancer therapy-related cardiac dysfunction in anthracycline-treated breast cancer patients: a retrospective study.

Kuroda J, Oikawa M, Tokuda E, Tachibana K, Sasaki E, Ohtake T, Takeishi Y, Saji S.

Support Care Cancer. 33 ( 1 ) 8 2024年12月

Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial).

Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K, Iwakuma N, Okamura T, Kobayashi T, Katagiri Y, Kitada M, Tomioka N, Miyoshi Y, Shigematsu H, Miyashita M, Ishiguro H, Masuda N, Saji S.

Breast Cancer Res Treat. 208 ( 2 ) 253 - 262 2024年11月

Usefulness of urine dipstick test in the management of adverse events associated with immune checkpoint inhibitors.

Izumi K, Iyoda T, Yokota A, Kanno M, Hoshi M, Tokuda E, Sasaki E, Kanazawa K, Kuroda J, Saji S.

Support Care Cancer. 32 ( 11 ) 735 2024年10月

Ipatasertib plus Paclitaxel for patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.

Dent RA, Kim SB, Oliveira M, Barrios C, O'Shaughnessy J, Isakoff SJ, Saji S, Freitas-Junior R, Philco M, Bondarenko I, Lian Q, Bradley D, Hinton H, Wongchenko MJ, Reilly SJ, Turner N.

Clin Cancer Res. 30 ( 19 ) 4329 - 4338 2024年10月

Impact of immediate breast reconstruction on perioperative therapy: insights from a Japanese Nationwide Registry.

Sasada S, Kumamaru H, Hayashi N, Kinukawa N, Toi M, Jinno H, Saji S.

Breast Cancer. 31 ( 5 ) 909 - 916 2024年9月

進化する乳癌治療

佐治重衡、戸井雅和

Animus 119 3 - 10 2024年7月

Treatment patterns and clinical outcomes in patients with metastatic triple-negative breast cancer: a large-scale data analysis using the Japanese claims database.

Kimura T, Takami T, Piao Y, Ntalla I, Saji S.

Breast Cancer Res Treat. 206 ( 1 ) 91 - 103 2024年7月

Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan.

Shimomura A, Sagara Y, Koto R, Fujiwara M, Kanemura Y, Kitagawa H, Saji S.

Breast Cancer. 31 ( 4 ) 581 - 592 2024年7月

The Japanese breast cancer society clinical practice guidelines for radiation treatment of breast cancer, 2022 edition.

Yoshimura M, Yamauchi C, Sanuki N, Hamamoto Y, Hirata K, Kawamori J, Kawamura M, Ogita M, Yamamoto Y, Iwata H, Saji S.

Breast Cancer. 31 ( 3 ) 347 - 357 2024年5月

Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines.

Hattori M, Honma N, Nagai S, Narui K, Shigechi T, Ozaki Y, Yoshida M, Sakatani T, Sasaki E, Tanabe Y, Tsurutani J, Takano T, Saji S, Masuda S, Horii R, Tsuda H, Yamaguchi R, Toyama T, Yamauchi C, Toi M, Yamamoto Y.

Breast Cancer. 31 ( 3 ) 335 - 339 2024年5月

The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.

Yamamoto Y, Yamauchi C, Toyama T, Nagai S, Sakai T, Kutomi G, Yoshimura M, Kawai M, Ohtani S, Kubota K, Nakashima K, Honma N, Yoshida M, Tokunaga E, Taira N, Iwata H, Saji S.

Breast Cancer. 31 ( 3 ) 340 - 346 2024年5月

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer.

Park KH, Loibl S, Sohn J, Park YH, Jiang Z, Tadjoedin H, Nag S, Saji S, Md Yusof M, Villegas EMB, Lim EH, Lu YS, Ithimakin S, Tseng LM, Dejthevaporn T, Chen TW, Lee SC, Galvez C, Malwinder S, Kogawa T, Bajpai J, Brahma B, Wang S, Curigliano G, Yoshino T, Kim SB, Pentheroudakis G, Im SA, Andre F, Ahn JB, Harbeck N

ESMO open 9 ( 5 ) 102974 2024年5月

Treatment patterns, healthcare resource utilization and outcomes for early stage triple-negative breast cancer in Japan.

Sanno H, Taniguchi K, Yoshimoto Y, Saji S

Future Oncol. 20 ( 13 ) 833 - 849 2024年4月

Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.

Takeshita T, Iwamoto T, Niikura N, Watanabe K, Kikawa Y, Kobayashi K, Iwakuma N, Okamura T, Tada H, Ozaki S, Okuno T, Toh U, Yamamoto Y, Tsuneizumi M, Ishiguro H, Masuda N, Saji S

ESMO open 9 ( 4 ) 102385 2024年4月

Protecting the Brain: Novel Strategies for Preventing Breast Cancer Brain Metastases through Selective Estrogen Receptor β Agonists and In Vitro Blood-Brain Barrier Models.

Kirchner J, Völker E, Shityakov S, Saji S, Förster CY.

Int J Mol Sci 25 ( 6 ) 3379 2024年3月

　前のページ- 次のページ　

<佐治 重衡>

論文 - 佐治 重衡

<佐治　重衡>

論文 - 佐治　重衡